Evercore Maintains Medtronic(MDT.US) With Buy Rating, Raises Target Price to $104

Evercore維持美敦力(MDT.US)買入評級，上調目標價至104美元

moomoo資訊 · 10/01 09:31 · 評級/大行評級

Evercore analyst Vijay Kumar maintains $Medtronic (MDT.US)$ with a buy rating, and adjusts the target price from $100 to $104.

According to TipRanks data, the analyst has a success rate of 57.6% and a total average return of 5.6% over the past year.

AnalystRecentRatingAutoNews_201438_20241001_b878eb2abb1e0d8afc4d14e458b2d2d6ca307441_1727872220847723_mm_en

Furthermore, according to the comprehensive report, the opinions of $Medtronic (MDT.US)$'s main analysts recently are as follows:

There is curiosity about whether the recent uptrend in medical technology stocks is sustainable as companies approach their third-quarter financial disclosures. The sentiment heading into earnings season is tinged with caution, given that the third quarter is traditionally challenging for the MedTech sector, with a particular focus on the outlook for 2025. Additionally, forthcoming commentary about projections for the next year might temper stock price movements in the short term.
In the MedTech sector, trends toward sustained utilization into the third quarter and a strong capital expenditure forecast for the upcoming year are observed. The life science tools segment is expected to see improvements in bioprocess trends in the latter half of the year, although there is ongoing discussion regarding the prospects for instrument sales and the impact of Chinese economic measures, given the recent performance of stocks in this area. Furthermore, Medtronic, among others in the sector, is being recognized for its potential performance leading into the third quarter financial results.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

Evercore分析師Vijay Kumar維持$美敦力 (MDT.US)$買入評級，並將目標價從100美元上調至104美元。

根據TipRanks數據顯示，該分析師近一年總勝率為57.6%，總平均回報率為5.6%。

AnalystRecentRatingAutoNews_201438_20241001_b878eb2abb1e0d8afc4d14e458b2d2d6ca307441_1727872220847723_mm_tc

此外，綜合報道，$美敦力 (MDT.US)$近期主要分析師觀點如下：

隨着各公司接近第三季度財務披露，醫療科技股最近的上漲趨勢是否可持續，人們對此感到好奇。鑑於第三季度傳統上對醫療科技行業具有挑戰性，特別關注2025年的前景，進入業績期的情緒略顯謹慎。此外，即將發表的關於明年預測的評論可能會在短期內緩和股價的走勢。
在醫療技術領域，可以觀察到第三季度的持續利用趨勢，以及對來年的強勁資本支出預測。生命科學工具板塊的生物工藝趨勢預計將在下半年有所改善，儘管鑑於該領域股票的近期表現，有關儀器銷售前景和中國經濟措施的影響的討論仍在繼續。此外，美敦力以及該行業的其他公司因其在第三季度財務業績之前的潛在表現而獲得認可。

提示:

TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。

TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。

分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。

總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

Evercore Maintains Medtronic(MDT.US) With Buy Rating, Raises Target Price to $104

Evercore Maintains Medtronic(MDT.US) With Buy Rating, Raises Target Price to $104

風險及免責聲明

聲明